Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONC201 in Relapsed/Refractory Non-Hodgkin's Lymphoma
NCT02420795Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2015
- Primary completion
- Nov 2020
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dordaviprone in non-Hodgkin lymphoma (NHL), mantle cell lymphoma (MCL), central nervous system lymphoma, sponsored by University of Texas MD Anderson Cancer Center. Started Nov 2015; status: terminated.
02
Drugs
dordaviprone
03
Conditions
non-Hodgkin lymphoma (NHL)mantle cell lymphoma (MCL)central nervous system lymphoma
Beyond the preview
Go deeper on NCT02420795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02420795.